Peter Istvan and David Newall founded “Pedaling for Parkinson’s” in 2011 as an annual cycling fundraising event to support Parkinson’s Canada and the Parkinson’s disease (PD) community. This year, “Pedaling for Parkinson’s” reached a new cumulative milestone, raising more than $1 million, which was made possible with the help of…
News
Quantifying changes in fluid in a specific brain area, using a magnetic resonance imaging (MRI)-based method, could provide a way to track brain damage in patients with Parkinson’s disease, a new study suggests. The study, “Progression marker of Parkinson’s disease: a 4-year multi-site imaging study,” appeared in the journal Brain.
The cognitive science company Cogstate received approval to market a new digital cognitive assessment tool to assist healthcare professionals in measuring cognition in patients ages 6 to 99, either in-clinic or at home. This tool, called the Cognigram, could help measure the progression of Parkinson’s disease and other illnesses. The Cognigram can…
According to a recent study, a newly discovered biomarker, free water, can track changes in the brain that are associated with Parkinson’s disease, which ultimately may aid in developing new drugs that could slow disease progression. “This finding is a potential game changer as it could shift the way Parkinson’s disease clinical…
Prexton Therapeutics has initiated a new Phase 2 clinical trial to assess the safety and effectiveness of its investigational therapy Foliglurax (PXT002331) in Parkinson’s disease patients treated with levodopa, but who are experiencing end-of-dose wearing off and levodopa-induced dyskinesia (involuntary movements). Levodopa is the most important first-line medication for the management of Parkinson’s,…
Acadia Pharmaceuticals, the maker of Nuplazid (pimavanserin), an oral medication to treat hallucinations and delusions associated with Parkinson’s disease (PD), was ranked 11th on Forbes Magazine’s 2017 list of the “World’s Most Innovative Growth Companies.” Forbes’ ranking is based on the ‘innovation premium’ of each…
Researchers are one step closer to fully understanding how a group of proteins, called the AMPA receptors, work — potentially gaining an insight into how neurological diseases like Parkinson’s develop in the brain, a new study reports. These findings may also help in the design of new treatment approaches. The study, titled…
In this video from Parkinson’s UK, people living with Parkinson’s disease talk about the effect the condition has had on their lives and offer some tips for anyone who has been recently diagnosed. MORE: Seven hand exercises for people with Parkinson’s disease Some of…
Hong Kong has issued a patent to Intec Pharma for its investigational Accordion Pill Carbidopa/Levodopa (AP-CD/LD) drug delivery for Parkinson’s disease symptoms in advanced patients. The patent (HK1158545) is titled “Carbidopa/Levodopa Gastroretentive Drug Delivery” and is scheduled to remain active until April 2029. The patent belongs to Intec’s IN-7 patent family that…
News
Prana and Takeda Will Investigate PBT434 as Treatment for Gastrointestinal Damage in Parkinson’s
Prana Biotechnology and Takeda Pharmaceuticals International are teaming up to investigate whether Prana’s PBT434 can improve gastrointestinal damage associated with Parkinson’s disease. PBT434 showed promise as a treatment for neuronal loss and movement problems in mice with Parkinson’s, according to a preclinical-trial study. The collaboration will deal with…
Recent Posts
- How to minimize stress while traveling with Parkinson’s disease
- New PET tracer helps scientists ‘see’ Parkinson’s toxic protein clumps
- Tech duo to advance brain-penetrating drugs for CNS disorders
- New trial offers extended buntanetap access for people with Parkinson’s
- Trial testing Crexont for advanced Parkinson’s kicks off in Europe